Circulating HMGB1 is increased in myelodysplastic syndrome but not in other bone marrow failure syndromes: proof-of-concept cross-sectional study.
Elia Apodaca-ChávezRoberta Demichelis-GómezAdriana Rosas-LópezNancy R Mejía-DomínguezIsabela Galvan-LópezMeghan AddorosioKevin J TraceySergio Iván Valdés-FerrerPublished in: Therapeutic advances in hematology (2022)
These observations indicate that circulating HMGB1 is increased in patients with MDS. HMGB1 (but not IL-1β or TNF-α) differentiated between MDS and other BM failures, suggesting that HMGB1 may be mechanistically involved in MDS and a druggable target to decrease inflammation in MDS.